Diabetes Prevention Interventions and Outcomes

The field of diabetes prevention has advanced through multifaceted strategies aimed at halting or delaying the onset of type 2 diabetes in high-risk individuals. At its core, prevention revolves around early identification of prediabetes—a state of impaired glucose regulation—and subsequent deployment of interventions that notably reduce progression to overt diabetes. Lifestyle modification, encompassing tailored nutritional advice, increased physical activity and behavioural support, consistently achieves risk reductions of around 25–60% over three to five years by improving insulin sensitivity and promoting weight loss. Pharmacological prevention, chiefly with metformin, augments these benefits by lowering hepatic glucose output and enhancing peripheral glucose uptake; combined approaches of metformin with lifestyle changes have yielded additional risk reductions of 10–15%. Emerging interventions include digital health platforms for remote monitoring, community-based peer support models, and personalised risk communications, all aimed at broadening reach and adherence. Outcomes extend beyond glycaemic thresholds to include prevention of microvascular and macrovascular complications, improvements in quality of life and potential cost savings for health systems. Global implementation challenges remain, notably in translating clinical trial efficacy into real-world effectiveness across diverse socioeconomic and cultural contexts.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Diabetes Prevention Interventions and Outcomes publication trend

The graph below shows the total number of articles in diabetes prevention interventions and outcomes across all publications each year (not limited to Nature Index journals).

Technical terms

Prediabetes: Intermediate state of blood glucose elevation below diabetic thresholds, indicating high risk of progression to type 2 diabetes.

Impaired glucose tolerance (IGT): Form of prediabetes defined by elevated two-hour plasma glucose in the oral glucose tolerance test.

HbA1c: Glycated haemoglobin measure reflecting average blood glucose levels over the preceding two to three months.

Lifestyle intervention: Structured programme of dietary modification, increased physical activity and behavioural support aimed at improving metabolic risk factors.

Metformin: Oral biguanide drug that lowers blood glucose by reducing hepatic glucose production and enhancing insulin sensitivity.

Randomised controlled trial (RCT): Study design in which participants are randomly allocated to intervention or control groups to objectively assess efficacy.

References

1. Metformin for the prevention of diabetes among people with HIV and either impaired fasting glucose or impaired glucose tolerance (prediabetes) in Tanzania: a Phase II randomised placebo-controlled trial. Diabetologia (2023).
2. Metformin plus lifestyle interventions versus lifestyle interventions alone for the delay or prevention of type 2 diabetes in individuals with prediabetes: a meta-analysis of randomized controlled trials. Diabetology & Metabolic Syndrome (2024).
3. Comparing the effectiveness of metformin with lifestyle modification for the primary prevention of type II diabetes: a systematic review and meta-analysis. BMC Endocrine Disorders (2023).